Items where authors include "Davies, FE"
Up a levelArticle
Thompson, MA, Boccadoro, M, Leleu, X et al. (26 more authors) (2023) Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia, 23 (3). e171-e181. ISSN 2152-2650
Panopoulou, A, Cairns, DA orcid.org/0000-0002-2338-0179, Holroyd, AE et al. (13 more authors) (2022) Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients. Blood. ISSN 0006-4971
Shahin, M, Pawlyn, C, Weinhold, N et al. (14 more authors) (2022) The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma. Blood, 140 (Supplement 1). pp. 4232-4233. ISSN 0006-4971
Agbuduwe, C, Iqbal, G, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (12 more authors) (2022) Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials. Blood Advances, 6 (17). pp. 5113-5123. ISSN 2473-9529
de Tute, RM, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2022) Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 40 (25). pp. 2889-2900. ISSN 0732-183X
Caro, J, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22 (4). E279-E284. ISSN 2152-2650
Giles, HV, Cook, MA, Drayson, MT et al. (12 more authors) (2021) Redefining Non-measurable Multiple Myeloma Using Mass Spectrometry. Blood. ISSN 0006-4971
Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924
Weinhold, N, Salwender, HJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (15 more authors) (2021) Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients. Haematologica. ISSN 0390-6078
Hájek, R, Minařík, J, Straub, J et al. (33 more authors) (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology. fon-2020-1225. ISSN 1479-6694
Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 192 (5). bjh.16945. pp. 853-868. ISSN 0007-1048
Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277
Shah, V, Sherborne, AL, Johnson, DC et al. (16 more authors) (2020) Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 34. pp. 3091-3096. ISSN 0887-6924
Jackson, GH, Davies, FE, Pawlyn, C et al. (20 more authors) (2020) Lenalidomide Before And After ASCT For Transplant-Eligible Patients Of All Ages In The Randomized, Phase III, Myeloma XI Trial. Haematologica. haematol.2020.247130. ISSN 0390-6078
Bradbury, CA, Craig, Z orcid.org/0000-0001-9930-6648, Cook, G orcid.org/0000-0003-0223-3652 et al. (14 more authors) (2020) Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials. Blood. ISSN 0006-4971
Boyle, EM, Ashby, C, Tytarenko, R et al. (25 more authors) (2020) BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 26 (10). pp. 2422-2432. ISSN 1078-0432
Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 6 (12). e616-e629. ISSN 2352-3026
Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078
Costello, C, Davies, FE, Cook, G orcid.org/0000-0003-0223-3652 et al. (16 more authors) (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology, 15 (13). pp. 1411-1428. ISSN 1479-6694
Cook, G orcid.org/0000-0003-0223-3652, Royle, K-L, Pawlyn, C et al. (10 more authors) (2019) A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematology, 6 (3). pp. 154-166. ISSN 2352-3026
Colombano, G, Caldwell, JJ, Matthews, TP et al. (18 more authors) (2019) Binding to an unusual inactive kinase conformation by highly selective inhibitors of inositol-requiring enzyme 1a kinase-endoribonuclease. Journal of Medicinal Chemistry, 62 (5). pp. 2447-2465. ISSN 0022-2623
Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (1). pp. 57-73. ISSN 1470-2045
Went, M, Sud, A, Speedy, H et al. (52 more authors) (2018) Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal, 9. ARTN 1. ISSN 2044-5385
Shah, V, Johnson, DC, Sherborne, AL et al. (19 more authors) (2018) Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 132 (23). pp. 2465-2469. ISSN 0006-4971
Yadav, P, Cockwell, P, Cook, M et al. (10 more authors) (2018) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrology, 19 (1). 178. ISSN 1471-2369
Royle, K-L, Gregory, WM orcid.org/0000-0003-2641-8416, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (8 more authors) (2018) Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. British Journal of Haematology, 182 (6). pp. 816-829. ISSN 0007-1048
Johnson, DC, Lenive, O, Mitchell, J et al. (14 more authors) (2017) Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, 130 (14). pp. 1639-1643. ISSN 0006-4971
Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385
Pawlyn, C, Kaiser, MF, Heuck, C et al. (20 more authors) (2016) The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clinical Cancer Research, 22 (23). pp. 5783-5794. ISSN 1078-0432
Mitchell, JS, Li, N, Weinhold, N et al. (55 more authors) (2016) Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature Communications, 7. 12050.
de Tute, RM, Rawstron, AC, Gregory, WM et al. (9 more authors) (2016) Minimal Residual Disease Following Autologous Stem Cell Transplant In Myeloma: Impact On Outcome Is Independent Of Induction Regimen. Haematologica, 101 (2). e69-e71. ISSN 0390-6078
Walker, BA, Boyle, EM, Wardell, CP et al. (24 more authors) (2015) Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 33 (33). pp. 3911-3920. ISSN 0732-183X
Mitchell, JS, Johnson, DC, Litchfield, K et al. (8 more authors) (2015) Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Scientific Reports, 5. 12473. ISSN 2045-2322
Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 6. ARTN 6997.
Proceedings Paper
Shah, V, Johnson, DC, Sherborne, AL et al. (18 more authors) (2018) Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, California, USA. American Society of Hematology , p. 2000.
Hajek, R, Terpos, E, Lee, HC et al. (20 more authors) (2018) Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Bygrave, CA, Pawlyn, C, Davies, FE et al. (19 more authors) (2018) Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Jackson, GH, Davies, FE, Pawlyn, C et al. (18 more authors) (2018) A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San DIego, California, USA. American Society of Hematology , p. 302.
Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2014) Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: BLOOD. 56th ASH Annual Meeting 2014, 06-09 Dec 2014, San Francisco, California, USA. American Society of Hematology .